[Apha Biz=(Chicago) Reporter Paul Lee] LG Chem is trying to localize infant combination vaccine, which is entirely dependent on imports.
The LG Chem announced on the 1st that it recently registered the first clinical trial of aP-based 6-ga combination vaccine APV006 in Korea.
APV006 is a vaccine that prevents six infectious diseases (diphtheria, tetanus, whooping cough, polio, meningitis, hepatitis B). The number of vaccinations can be reduced twice in total compared to the commonly used 5-valent vaccine (diphtheria, tetanus, pertussis, polio, meningitis) in Korea. A total of six separate doses of the pentavalent vaccine and the hepatitis B vaccine, and a total of four doses of the hexavalent vaccine.
The first phase of the clinical trial will be conducted on 42 healthy adults at Seoul National University Hospital. APV006 and third-party 6 will compare and evaluate the safety and immunogenesis between combination vaccine.
The LG Chem said it will further stabilize the domestic infant vaccination supply chain by commercializing APV006. The LG Chem plans to invest more than 200 billion won in APV006 clinical development and facility construction and commercialize it in Korea by 2030.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
